Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 3/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | IL1RN | P18510 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1790572 | 0.82 | MAPT (0.64) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL15480538 | 0.81 | MEN1 (0.71) | MEN1KMT2AHDAC1ALDH1A1PKM | |
| SCHEMBL7531867 | 0.80 | MEN1 (0.69) | MEN1KMT2ATDP1HDAC1ALDH1A1 | |
| SCHEMBL15948134 | 0.80 | MEN1 (0.69) | MEN1KMT2AHDAC1ALDH1A1PKM | |
| SCHEMBL893905 | 0.79 | CA12 (0.73) | MEN1KMT2ACA1CA2HDAC1 | |
| SCHEMBL8367726 | 0.79 | TDP1 (0.78) | MEN1KMT2ATDP1CA2ALDH1A1 | |
| SCHEMBL2561573 | 0.78 | KMT2A (1.00) | MEN1KMT2ACA1CA2ALDH1A1 | |
| SCHEMBL12010899 | 0.78 | MAPT (0.72) | MEN1KMT2ATDP1CA1CA2 | |
| SCHEMBL69804 | 0.78 | MAPT (0.61) | MEN1KMT2ACA1CA2HDAC1 | |
| SCHEMBL3052663 | 0.78 | BDKRB1 (0.60) | KMT2ACA1CA2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197437-A1 | COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070161563-A1 | A DEVICE FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-07-12 | — | — | US | disclosed |
| US-7229966-B2 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070129299-A1 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PYY PEPTIDE | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-06-07 | — | — | US | disclosed |
| US-7186691-B2 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157426-B2 | such as peptide YY, Neuropeptide Y, or Pancreatic polypeptide with solubilizing agent (cyclodextran), chelating agent (ethylenediamine tetraacetic acid), and polyol such as sucrose | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1715885-A2 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY | Nastech Pharmaceutical Company Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060134130-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| US-7005141-B2 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES INC. (US) | 2006-02-28 | — | — | US | disclosed |
| CN-1726044-A | Compositions and methods for enhancing mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARM CO (US) | 2006-01-25 | — | — | CN | disclosed |
| EP-1025840-A2 | Oral drug compositions and methods | Emisphere Technologies, Inc. (US) | 2000-08-09 | — | — | EP | disclosed |
| US-5958457-A | MIXTURES OF ANTIGENS WITH ADJUVANTS AND ACYLATED AMINO ACIDS OR SALTS, POLYMERS OR SULFONATED AMINO ACIDS | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5766633-A | MODIFIED AMINO ACID CARRIER, BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5709861-A | PEPTIDES WITH ANTIGENS AND PROCESS FOR MIXING | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-01-20 | — | — | US | disclosed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996021464-A9 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | — | 1996-11-14 | — | — | WO | disclosed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| US-4728594-A | PHOTORESISTS FOR MAKING SEMICONDUCTORS | HITACHI CHEMICAL CO., LTD. (JP) | 1988-03-01 | — | — | US | disclosed |
| EP-0189271-A2 | Photosensitive composition | Hitachi Chemical Co., Ltd. (JP) | 1986-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134130-A1 | Oral drug delivery compositions and methods | ADM2, PTMS, DNPEP | MEN1 1466/4885KMT2A 887/4885TDP1 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.